Publications

Transcriptome Profiling Reveals New Insights into the Immune Microenvironment and Upregulation of Novel Biomarkers in Metastatic Uveal Melanoma.

Krishna Y, Acha-Sagredo A, Sabat-Pośpiech D, Kipling N, Clarke K, Figueiredo CR, Kalirai H, Coupland SE. Cancers (Basel). 2020 Sep 30;12(10):E2832.

Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells (2020)

Machado FC, Girola N, Maia VSC, Bergami-Santos PC, Morais AS, Azevedo RA, Figueiredo CR, Barbuto JAM, Travassos LR. Front Immunol. 2020 Jan 15;10:3122.

New tools to prevent cancer growth and spread: a ‘Clever’ approach (2020)

Hollmén M, Figueiredo CR, Jalkanen S. Br J Cancer. 2020 Aug;123(4):501-509.

Loss of BAP1 Expression Is Associated With an Immunosuppressive Microenvironment in Uveal Melanoma, With Implications for Immunotherapy Development. (2020)

Figueiredo CR, Kalirai H, Sacco JJ, Azevedo RA, Duckworth A, Slupsky JR, Coulson JM, Coupland SE. J Pathol. 2020 Apr;250(4):420-439. 

CDR-1 Rb44 Peptide, Which Targets the Microtubule Network in Melanoma Cells (2019)

Girola N, Resende-Lara PT, Figueiredo CR, Massaoka MH, Azevedo RA, Cunha RLOR, Polonelli L, Travassos LR. Front Oncol. 2019 Jan 25;9:25.

Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma (2018)

Figueiredo CR, Azevedo RA, Mousdell S, Resende-Lara PT, Ireland L, Santos A, Girola N, Cunha RLOR, Schmid MC, Polonelli L, Travassos LR, Mielgo A. Front Immunol. 2018 May 23;9:1132.

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer (2018)

Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG, Weyer-Czernilofsky U, Bogenrieder T, Schmid M, Mielgo A. Oncogene. 2018 Apr;37(15):2022-2036.

Recent breakthroughs in metastatic uveal melanoma: a cause for optimism? (2018)

Sacco JJ, Kalirai H, Kenyani J, Figueiredo CR, Coulson JM, Coupland SE(A2 Katsausartikkeli tieteellisessä aikauslehdessä)

A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo (2015)

Figueiredo CR, Matsuo AL, Azevedo RA, Massaoka MH, Girola N, Polonelli L, Travassos LR. Sci Rep. 2015 Sep 22;5:14310.

Anti-tumor activities of peptides corresponding to conserved complementary determining regions from different immunoglobulins (2014)

PeptidesFigueiredo CR, Matsuo AL, Massaoka MH, Polonelli L, Travassos LR(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)

β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma (2012)

Arruda DC, Santos LC, Melo FM, Pereira FV, Figueiredo CR, Matsuo AL, Mortara RA, Juliano MA, Rodrigues EG, Dobroff AS, Polonelli L, Travassos LR. J Biol Chem. 2012 Apr 27;287(18):14912-22. 

A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity (2011)

Molecular Cancer ResearchMatsuo AL, Juliano MA, Figueiredo CR, Batista WL, Tanaka AS, Travassos LR. Mol Cancer Res. 2011 Nov;9(11):1471-8.

Role of SOCS-1 Gene on Melanoma Cell Growth and Tumor Development (2011)

Scutti JA, Matsuo AL, Pereira FV, Massaoka MH, Figueiredo CR, Moreira DF, Belizário JE, Travassos LR(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)

Pagination